UniCAR Therapy and Terumo BCT Collaborate to Advance CAR T-Cell Therapies and Create a Shanghai, China Center of Excellence

LAKEWOOD, Colo., Oct. 09, 2018 (GLOBE NEWSWIRE) — Shanghai UniCAR-Therapy Bio-Medicine Technology Co. chose Terumo BCT and its cell expansion devices to automate its cell therapy manufacturing process for chimeric antigen receptor (CAR) T-cell therapies. Privately held, UniCAR will open their Center of Excellence for Terumo BCT’s technologies in Shanghai in November.

Terumo BCT is a global leader in blood component, therapeutic apheresis and cellular therapy technologies. The company provides flexible solutions for CAR T-cell developers and manufacturers, including the Quantum® Cell Expansion System, in use at UniCAR today.Terumo BCT

“Compared to the manual method of cell expansion, we save time and increase the quality of cells and viruses we grow using the Quantum system,” says Dr. Yu Lei, a pioneer in the gene therapy field and Chief Executive Officer, UniCAR. “It only makes sense to share best practices and showcase technologies that are driving innovation in our growing industry.”

In 2018, UniCAR submitted four applications for CAR T-cell drug candidates as investigational new drugs (INDs) to China’s National Medical Products Administration (NMPA). UniCAR’s advanced CAR T2.0 technologies are designed to reduce the side effects of treatments and improve patient outcomes.

“The science and development in the cell and gene therapy space are rapidly evolving. Both UniCAR and Terumo BCT are at the forefront of this quickly changing landscape,” says Cindy Ng, Senior Vice President, Global Commercial, Terumo BCT. “Our collaboration has the potential to touch many patients’ lives.”

In addition to automating cell expansion manufacturing with the Quantum system, Terumo BCT continues to deliver high-levels of service to support its customer’s innovations. The Finia® Fill and Finish System, one of the company’s latest technology in development, is designed to automate the final step of cell processing which includes cooling, mixing and aliquoting doses of cell therapies. The company’s COBE® Spectra Apheresis System and Spectra Optia® Apheresis System are extensively used in the industry to collect high-quality white blood cells—the first step in CAR T-cell therapies.

About UniCAR
China-based UniCAR Therapy is a pioneer in the industry of cancer immunotherapy. The company collaborates with top-ranked hospitals specializing in hematological malignancies, including leukemia, lymphoma and multiple myeloma. To date, more than 400 patients have benefitted from UniCAR’s immunotherapeutic products. The company holds more than 30 patents of CAR T-cell technology and is dedicated to the extended application of the next generation of CAR T-cell therapies with enhanced efficacy and safety profiles.

About Terumo BCT
Terumo BCT, a global leader in blood component, therapeutic apheresis and cellular therapy technologies, is the only company with the unique combination of apheresis collections, manual and automated whole blood processing, and pathogen reduction technologies. We believe in the potential of blood to do even more for patients than it does today. This belief inspires our innovation and strengthens our collaboration with customers.

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/36fcf676-d50a-4406-9f02-e11126302966

Media Contacts
Terumo BCT 
Bradley Hein 
+1.303.542.5396
press@terumobct.com

UniCAR Therapy
Kang Li Qing
+86 13162512992
liqing.kang@unicar-therapy.com

You may also like...